白细胞介素23轴在炎症性肠病的发病机制中起关键作用。
The IL23 axis plays a key role in the pathogenesis of IBD.
作者信息
McGovern Dermot, Powrie Fiona
机构信息
Imperial College, London, Hammersmith Hospital Campus Du Cane Road, London W12 0HS, UK.
出版信息
Gut. 2007 Oct;56(10):1333-6. doi: 10.1136/gut.2006.115402.
Abstract
Exciting new results from a genetic study in humans and functional studies in mice have pinpointed interleukin 23 (IL23) and its receptor as a key pathway in the pathogenesis of inflammatory bowel disease (IBD). These findings reveal a hitherto unappreciated role for the IL23 axis in intestinal inflammation and may open new avenues for development of therapeutic strategies in IBD.
摘要
一项针对人类的基因研究以及针对小鼠的功能研究取得了令人振奋的新成果，这些成果已明确白细胞介素23（IL23）及其受体是炎症性肠病（IBD）发病机制中的关键途径。这些发现揭示了IL23轴在肠道炎症中迄今未被认识到的作用，并可能为IBD治疗策略的开发开辟新途径。
相似文献
1
The IL23 axis plays a key role in the pathogenesis of IBD.
Gut. 2007 Oct;56(10):1333-6. doi: 10.1136/gut.2006.115402.
2
IL23 induces IL23R recycling and amplifies innate receptor-induced signalling and cytokines in human macrophages, and the IBD-protective IL23R R381Q variant modulates these outcomes.
Gut. 2020 Feb;69(2):264-273. doi: 10.1136/gutjnl-2018-316830. Epub 2019 May 16.
3
IL23 Promotes Antimicrobial Pathways in Human Macrophages, Which Are Reduced With the IBD-Protective IL23R R381Q Variant.
Cell Mol Gastroenterol Hepatol. 2020;10(4):673-697. doi: 10.1016/j.jcmgh.2020.05.007. Epub 2020 May 29.
4
Pro-inflammatory miR-223 mediates the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease.
Genome Biol. 2016 Mar 30;17:58. doi: 10.1186/s13059-016-0901-8.
5
IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease.
Annu Rev Med. 2009;60:97-110. doi: 10.1146/annurev.med.60.051407.123757.
6
Clinical aspects of inflammatory bowel disease.
Eur J Immunol. 2009 Aug;39(8):2026-30. doi: 10.1002/eji.200939601.
7
Immunopathogenesis of inflammatory bowel disease: current concepts.
Curr Opin Gastroenterol. 2007 Jul;23(4):365-9. doi: 10.1097/MOG.0b013e3281c55eb2.
8
GWA studies: rewriting the story of IBD.
Trends Genet. 2009 Mar;25(3):137-46. doi: 10.1016/j.tig.2009.01.001. Epub 2009 Feb 13.
9
Inflammatory bowel disease: beyond the boundaries of the bowel.
Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):401-10. doi: 10.1586/egh.11.23.
10
After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?
Int Immunopharmacol. 2007 Apr;7(4):409-16. doi: 10.1016/j.intimp.2006.09.024. Epub 2006 Nov 13.
引用本文的文献
1
The Place of Appendicectomy in Inflammatory Bowel Disease-A Review.
ANZ J Surg. 2025 Jun;95(6):1091-1095. doi: 10.1111/ans.70157. Epub 2025 May 15.
2
Exploring the Therapeutic and Gut Microbiota-Modulating Effects of Qingreliangxuefang on IMQ-Induced Psoriasis.
Drug Des Devel Ther. 2025 Apr 28;19:3269-3291. doi: 10.2147/DDDT.S492044. eCollection 2025.
3
Gut instinct: harnessing the power of probiotics to tame pathogenic signaling pathways in ulcerative colitis.
Front Med (Lausanne). 2024 Sep 11;11:1396789. doi: 10.3389/fmed.2024.1396789. eCollection 2024.
4
Effects of DNA methylation and its application in inflammatory bowel disease (Review).
Int J Mol Med. 2024 Jun;53(6). doi: 10.3892/ijmm.2024.5379. Epub 2024 May 2.
5
Role of pH-sensing receptors in colitis.
Pflugers Arch. 2024 Apr;476(4):611-622. doi: 10.1007/s00424-024-02943-y. Epub 2024 Mar 22.
6
OGR1 (GPR68) and TDAG8 (GPR65) Have Antagonistic Effects in Models of Colonic Inflammation.
Int J Mol Sci. 2023 Oct 3;24(19):14855. doi: 10.3390/ijms241914855.
7
Emerging Therapies for Ulcerative Colitis: Updates from Recent Clinical Trials.
Clin Exp Gastroenterol. 2023 Aug 17;16:147-167. doi: 10.2147/CEG.S375969. eCollection 2023.
8
Interleukins (Cytokines) as Biomarkers in Colorectal Cancer: Progression, Detection, and Monitoring.
J Clin Med. 2023 Apr 25;12(9):3127. doi: 10.3390/jcm12093127.
9
The Study of the Extracellular Matrix in Chronic Inflammation: A Way to Prevent Cancer Initiation?
Cancers (Basel). 2022 Nov 29;14(23):5903. doi: 10.3390/cancers14235903.
10
The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases.
Curr Issues Mol Biol. 2022 Apr 26;44(5):1851-1866. doi: 10.3390/cimb44050127.
本文引用的文献
1
A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1.
Nat Genet. 2007 Feb;39(2):207-11. doi: 10.1038/ng1954. Epub 2006 Dec 31.
2
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.
Science. 2006 Dec 1;314(5804):1461-3. doi: 10.1126/science.1135245. Epub 2006 Oct 26.
3
Interleukin-23 drives innate and T cell-mediated intestinal inflammation.
J Exp Med. 2006 Oct 30;203(11):2473-83. doi: 10.1084/jem.20061099. Epub 2006 Oct 9.
4
IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis.
J Exp Med. 2006 Oct 30;203(11):2485-94. doi: 10.1084/jem.20061082. Epub 2006 Oct 9.
5
TUCAN (CARD8) genetic variants and inflammatory bowel disease.
Gastroenterology. 2006 Oct;131(4):1190-6. doi: 10.1053/j.gastro.2006.08.008. Epub 2006 Aug 5.
6
CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration.
Nat Genet. 2006 Sep;38(9):1049-54. doi: 10.1038/ng1871. Epub 2006 Aug 27.
7
Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis.
J Immunol. 2006 Sep 1;177(5):2760-4. doi: 10.4049/jimmunol.177.5.2760.
8
Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology.
Immunity. 2006 Aug;25(2):309-18. doi: 10.1016/j.immuni.2006.05.017.
9
Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis.
J Clin Invest. 2006 May;116(5):1317-26. doi: 10.1172/JCI25308.
10
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6.
J Clin Invest. 2006 May;116(5):1310-6. doi: 10.1172/JCI21404.
Zotero 插件